Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|October 26, 2014
Lessons from the 2014 Next-Generation Pharmacistâ„¢ Award Finalists
Stephen Eckel, PharmD, MHA, BCPS, FASHP, divulges what he's learned from his fellow Next-Generation Pharmacistâ„¢ Award finalists.
Advertisement
Stephen Eckel, PharmD, MHA, BCPS, FASHP, divulges what he’s learned from his fellow Next-Generation Pharmacist™ Award finalists.
“When you start hearing their stories and learning from them, it really creates ways that you can then apply that internally so you can be successful in your own realm,” he says.
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
4
Building a BCMA Bispecific Around the Patient Experience, Not Just the Molecule
5